Top mRNA Therapeutics Companies

mRNA Therapeutics Market size was valued at USD 41.62 Billion in 2023 and is poised to grow from USD 42.45 Billion in 2024 to USD 49.74 Billion by 2032, growing at a CAGR of 2% during the forecast period (2025-2032).

The competitive environment of the global mRNA therapeutics market is made up of several key players. There is a mix of renowned pharmaceutical companies and rising biotech startups, along with innovative research institutes. Some industry leaders in this market are Pfizer, Moderna, CureVac, Translate Bio, BioNTech, and Arcturus Therapeutics. 'CureVac AG (Germany)', 'Roche Holding AG (Switzerland)', 'Pfizer Inc. (USA)', 'GlaxoSmithKline plc (United Kingdom)', 'Moderna, Inc. (USA)', 'Sanofi SA (France)', 'BioNTech SE (Germany)', 'Dynavax Technologies Corporation (USA)', 'Arcturus Therapeutics Holdings Inc. (USA)', 'AstraZeneca plc (United Kingdom)', 'Regeneron Pharmaceuticals, Inc. (USA)', 'Alnylam Pharmaceuticals, Inc. (USA)', 'Gilead Sciences, Inc. (USA)', 'Mylan N.V. (USA)', 'Novartis AG (Switzerland)', 'Modulus Therapeutics, Inc. (USA)', 'Catalent, Inc. (USA)', 'Translate Bio, Inc. (USA)', 'Ionis Pharmaceuticals, Inc. (USA)', 'Vertex Pharmaceuticals Incorporated (USA)'

The COVID-19 pandemic accelerated mRNA vaccine development, establishing mRNA technology as a powerful tool in combating infectious diseases.

This market has seen a growing and impactful trend. Cancer vaccines are being developed with the help of mRNA. This presents an impressive opportunity for breakthrough in oncology treatment and therapy.

North America asserted its dominance in the mRNA therapeutics market share, holding a substantial share of over 35.0%, and is poised to emerge as the fastest-growing region in the forecast period. This ascendancy can be attributed to several key factors, including the availability of significant research funding, the expansion of federal programs dedicated to advancing RNA-based medicines, and a burgeoning number of clinical trials. A case in point is the robust support provided by institutions such as The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories. Their unwavering backing for foundational research, including that conducted by Graham and other researchers, has played a pivotal role in the rapid development of COVID-19 vaccines. Notably, in response to the pandemic, the government injected an additional $10.5 billion into vaccine manufacturers, expediting the delivery of their products. These factors collectively underscore North America's position as a thriving hub for mRNA-based medicines and therapeutics.